Pfizer

Pfizer · Pharmaceuticals/Biotech

Tue, May 5, 2026·Before Market Open

PfizerPFEEarnings

01Wall Street Consensus

EPS$0.72

Revenue$14.2B

EPS$0.75+3.5%

Revenue$14.45B+3.8%

After-Hours ReactionRegular +2.5%

Adj. EPS $0.75 — beat consensus $0.72 by +3.5%
Revenue $14.45B — beat consensus $13.92B by +3.8%, +5% YoY
Launched and acquired portfolio +22% operational growth — primary driver
Eliquis (anticoagulant) — older-population demand recovery driving non-COVID sales
Vyndaqel (heart failure) and Padcev (urothelial cancer) — sustained growth
Comirnaty COVID vaccine and Paxlovid antiviral — declining but with reduced impact
FY2026 revenue guide $59.5-62.5B reaffirmed
FY2026 adj. EPS guide $2.80-3.00 reaffirmed

Detail

Beat1Miss0Beat률 100%

분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

02Earnings Results

EPS$0.75+3.5%

Revenue$14.45B+3.8%

After-Hours ReactionRegular +2.5%

Adj. EPS $0.75 — beat consensus $0.72 by +3.5%
Revenue $14.45B — beat consensus $13.92B by +3.8%, +5% YoY
Launched and acquired portfolio +22% operational growth — primary driver
Eliquis (anticoagulant) — older-population demand recovery driving non-COVID sales
Vyndaqel (heart failure) and Padcev (urothelial cancer) — sustained growth
Comirnaty COVID vaccine and Paxlovid antiviral — declining but with reduced impact
FY2026 revenue guide $59.5-62.5B reaffirmed
FY2026 adj. EPS guide $2.80-3.00 reaffirmed